Osteopore Ltd.

As of December 31, 2025, Osteopore Ltd. carries a market capitalization of 1.64M, placing it among publicly traded companies globally. Its enterprise value stands at 3.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Osteopore Ltd. has 272.50M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 0.37, and the price-to-book ratio stands at -0.95.

These figures are as of December 31, 2025. The EV/Sales ratio of 1.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.77M versus a market cap of 1.64M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Osteopore Ltd. maintains a current ratio of 0.85, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -161.90, indicating conservative leverage, while an interest coverage ratio of -10.62 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -125.99, reflecting losses generated across the asset base. Inventory turnover of 1.85 indicates how many times Osteopore Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, Osteopore Ltd. recorded 1,672.00 in income tax expense. The company reported a pretax loss of -3.72M and -3.72M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Osteopore Ltd.'s stock has declined approximately 63.64% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

Over the twelve months ended December 31, 2025, Osteopore Ltd. generated 3.06M in revenue and converted that into -3.72M in net income, yielding earnings per share of -0.02. EBITDA reached -2.97M, while operating income came in at -3.41M.

As of December 31, 2025, Osteopore Ltd. holds 656,672.00 in cash and equivalents against 2.79M in total debt, resulting in a net debt position of 2.03M. Total book value stands at -1.73M, with working capital of -457,639.00 providing operational flexibility.

These figures cover the twelve months ended December 31, 2025.

Over the twelve months ended December 31, 2025, Osteopore Ltd. posted a gross margin of 77.51, reflecting its pricing power and cost economics. The operating margin of -111.56 and net profit margin of -121.76 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Total shareholder yield is negative at -162.27, meaning Osteopore Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Osteopore Ltd.'s most recent stock split took place on March 18, 2024 with a 59:330 split ratio.

As of December 31, 2025, Osteopore Ltd. has an Altman Z-Score of -13.89, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.